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TECHNICAL NOTE 
Animal model to study the effect of adrenal hormones on 
epithelial function 
RODOLFO S. MARTIN, WIL J. JONES, and JOHN P. HAYSLETT 
Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut 
The action of aldosterone to increase the renal excretion of 
potassium and reduce urinary losses of sodium has been known 
for nearly 30 years. Our understanding of the mechanism of 
action of aldosterone, however, has been derived primarily 
from in vitro studies on anuran and mammalian tissues. The 
interpretation of experiments performed in vivo has often been 
unclear because of technical problems related to maintaining 
plasma levels of endogenous adrenal hormones at basal or high 
physiological levels and uncertainties related to biological 
equivalent doses in studies where synthetic glucocorticoids 
have been used to substitute for cortisol or corticosterone. To 
evaluate the in vivo action of aldosterone and glucocorticoids 
on epithelial tissues, an experimental animal model was devel- 
oped in which chronic physiological levels of both types of 
adrenal hormones could be altered by experimental design. 
Methods. Studies were performed in male Sprague-Dawley 
rats (Camm Research Institute, Wayne, New Jersey) that were 
allowed free access to food and drinking solution. The following 
studies were performed. 
Plasma levels of aldosterone and corticosterone in animals 
with intact adrenal glands. Plasma was obtained between 9 
A.M. and 12 P.M. in unstressed (Basal) rats, killed by guillotine, 
and in rats anesthesized with Inactin, in a dose of 100 to 120 
mgtkg (Promonta, Hamburg, Germany), and subjected to acute 
renal clearance studies approximately 2 hr after the induction of 
anesthesia (Stressed). The clearance studies were performed to 
determine plasma aldosterone and corticosterone levels under 
several common experimental conditions. Three groups of 
animals were studied: 
( I )  Control. These animals were fed a paste diet prepared in 
our laboratory which contained sucrose 48%, casein 30%, lard 
lo%, corn oil 5%, vitamin fortification mixture 2% (Nutritional 
Biochemical Corporation, Cleveland, Ohio), NaCl 0.5%, 
K2HP04 1%, and a mineral mixture, as previously described 
[I]. This diet contained 0.13 mEq/g K and 0.10 mEq/g Na. Tap 
water was provided as the drinking solution. 
(2) High potassium diet. A regular chow (Purina Rat Chow, 
Ralston Purina, St. Louis, Missouri) was administered for 5 to 8 
days to which potassium chloride was added to provide a 
concentration of 1.56 mEq/g K. The drinking solution was tap 
water. 
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(3) Sodium deficiency. These animals were fed a sodium-free 
paste diet for 5 to 8 days and had free access to tap water. 
Adrenalectomized animals with hormone replacement. Ani- 
mals were lightly anesthesized with pentobarbitol, and bilateral 
adrenalectomy was performed by flank incisions. Hormone 
replacement with aldosterone and corticosterone was achieved 
in the following manner. 
Chronic infusion of aldosterone was performed with osmotic 
minipumps (model 2001 or 2002, Alza Corporation, Palo Alto, 
California) implanted in a subcutaneous tunnel in the interscap- 
ular area. Aldosterone was dissolved in an ethanol-0.15 M NaCl 
solution, in which final ethanol concentration did not exceed 
5%. To insure constant rates of infusion at the time of implanta- 
tion, the pumps were incubated in 0.15 M NaCl at 37'C for 4 hr 
before use. In vitro studies, using 3~ methoxy-inulin, demon- 
strated that infusion rates were approximately 1 pVhr for at 
least 1 week, as reported by the manufacturer. 
Since corticosterone is poorly soluble in saline and organic 
solvents, replacement dosages could not be administered by the 
minipump technique. Therefore, the hormone was implanted as 
pellets in the interscapular area. The method of pellet formation 
has been previously described [ 2 ] .  Briefly, corticosterone (Sig- 
ma Chemical Corp., St. Louis, Missouri) was weighted, careful- 
ly melted on a stainless steel spoon over a low gas flame, and 
poured into individual 5 x 5 mm holes drilled into a paraffin 
block. In studies in which less than 60 mg of corticosterone per 
pellet were used, cholesterol was added to the corticosterone to 
provide a final weight of 60 mg per pellet. Adrenalectomized 
animals not given the replacement of aldosterone were given 
0.15 M NaCl with 5% glucose as a drinking solution. In one 
group of animals dexamethasone was administered subcutane- 
ously in a dose of 5 pg1100 body weight at 12-hr intervals. 
Determination of transmural potential difference in rat colon. 
To determine the physiologic action of adrenal hormones on 
epithelia responsive to the action of aldosterone, the transmural 
potential difference (PD) was measured in the distal colon by 
methods previously described [3]. Since previous studies have 
shown that the PD varies along the course of the colon, 
measurements were made at 0.5-cm intervals from the anus to a 
site 6 cm proximal to the anus. 
Methods used to determine plasma aldosterone, corticoster- 
one, and dexamethasone levels. Plasma corticosterone levels 
were determined by the competitive protein binding method 
described by Murphy [4]. Briefly, two ethanol extractions of rat 
plasma (0.1 ml plasma: 1.0 ml ethanol) were combined, dried 
under nitrogen, and allowed to compete with tritiated cortico- 
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sterone (New England Nuclear Corp., Boston, Massachusetts)
for binding sites on human CBG at 4°C. After equilibration
CBG-bound corticosterone was separated from the unbound
fraction by the addition of dextran-coated charcoal, followed by
centrifugation. The supernatant was decanted into scintillation
fluid and the activity of 3H-corticosterone was determined in a
scintillation counter (Packard Tri-Carb, Packard Instruments,
Downers Grove, Illinois). The concentration of corticosterone
was calculated by comparing the percent of corticosterone
bound to unknowns with standards processed in the same way.
Measurement of plasma aldosterone was accomplished by
combining the chromatographic purification method of Buhler
et al [5] with a commercial aldosterone radioimmunoassay kit
(Diagnostic Products, Kald-2, Los Angeles, California). Purifi-
cation of the samples prior to radioimmunoassay was necessary
due to the relatively high crossreactivity of the commercial
aldosterone antiserum with corticosterone (manufacturer's in-
formation) and possibly with other substances occurring natu-
rally in rat plasma.
Direct radioimmunoassay of aldosterone in nonpurified plas-
ma samples from unstressed rats yielded values that were
several fold higher (35 ng/dl) than previously reported values of
5 to 10 ngldl for samples collected under comparable circum-
stances [6—8]. Similarly, samples from adrenalectomized rats
treated only with corticosterone replacement had apparent
aldosterone concentrations of 5.2 ng/dl that were inconsistent
with adrenalectomy. After the addition of the purification step
to the aldosterone assay, plasma samples both from unstressed
rats and adrenalectomized animals with corticosterone substitu-
tion alone yielded values consistent with previously reported
values, and averaged 4.60 0.7 ngldl and "undetectable,"
respectively.
Briefly, purification of the samples consisted of the following:
Methylene chloride extraction was performed in rat plasma and
plasma-based aldosterone standards (7.0 ml CH2CI2: 1.0 ml
sample). Five milliliters of the organic phase were evaporated 1
hr under nitrogen to dryness, reconstituted in small volumes
(0,1 ml) of ethyl acetate and iso-octane (0.4 ml), and the entire
0.5-mi volume was applied to small, disposable columns of
diatomaceous silica for chromatography. Subsequently, each
tube was rinsed with 0.05 ml ethyl acetate and 0.2 ml of iso-
octane. The entire volume of this rinse was applied to the
column. The entire plasma volume equivalent applied to the
column was 714 d. The columns were made from disposable 5-
ml glass pipettes (Kimble #72120-5110) which were shortened
by 7 cm, fire-polished, and plugged at the narrow end with a
glass bead. The packing material (approximately 1 glcolumn)
was acid-washed diatomaceous silica (Sigma Chemical Co.,
#D5384), thoroughly mixed with 40% ethylene glycol in water,
in a 3:1 (w/w) ratio.
Three successive washes (volume, 3.5 ml each) of increasing
concentrations of ethyl acetate in iso-octane were applied to the
columns. The first two washes (15 and 40% ethyl acetate) were
discarded. Aldosterone was eluted from the column with the
final wash of 60% ethyl acetate, All elutions were assisted by
the application of approximately 1.5 pounds pressure of nitro-
gen through a tubing-and-rubber-stopper manifold. The aldos-
terone-containing elutions were evaporated to dryness under
nitrogen and reconstituted in 1.5 ml borate-saline buffer, pH
8.4.
Radioimmunoassay was carried out according to the manu-
facturer's protocol and involved a '251-labeled aldosterone,
single antibody method, using dextran-coated charcoal to sepa-
rate antibody-bound from free hormone at 4°C. The antibody-
bound moiety was counted in a gamma counter (Searle Analyt-
ic, Model 1195). Standard curve results were plotted on log-log
paper, and the concentration of unknowns were estimated from
the standard curve.
The concentration of dexamethasone in rat plasma was
determined after the subcutaneous injection of 5 tgIl0O g body
weight. The injectate contained 200 Ci of 3H-dexamethasone
and a total of 20 g dexamethasone per milliliter of 0.15 M
NaCI. Plasma samples were obtained 10, 20, 30, 45, 60, 90, 120
and 180 mm after injection and dexamethasone was extracted
into 2 ml of dichloromethane (CH2CI2) from 50 l samples of
injectate and plasma, dried under nitrogen, and reconstituted in
Ultrafluor with acetic acid for counting a liquid scintillation
counter (Packard Tri-Carb). Plasma levels of dexamethasone
were calculated from the specific activity of the extracted
injectate.
Values are presented as the mean SEM. Comparison
between means was performed using Student's t test.
Results. Endogenous plasma levels of aldosterone and corti-
costerone. To replace adrenalectomized animals with physio-
logic levels of adrenal hormones, it was necessary to estimate
endogenous plasma levels in rats with intact adrenal glands
under various physiologic conditions. Plasma levels of aldoster-
one in control rats, animals on a high potassium diet, and
sodium deficient rats were measured under basal and un-
stressed conditions and are shown in the upper panel of Figure
1. In control animals the basal level was 4.6 0.7 ng/dl, which
agreed with previous reports [6—81, and rose to 62 7 ng/dl
after the stress of surgery and anesthesia. Levels in animals on
a high potassium diet were 35 7 and 125 25 ng/dl,
respectively, under the same conditions. In sodium-deprived
rats the basal level of aldosterone was elevated markedly to 473
66 ngldl, as previously reported [8].
Plasma corticosterone levels are shown in the lower panel of
Figure 1. The basal level of 9.0 1.8 g/dl in control animals
was increased to 30.0 1.2 by acute stress. Basal and stressed
values in animals on a high potassium diet were comparable to
levels in control animals under the same conditions. In sodium-
deprived rats the basal corticosterone level was 15 2.2 g/di.
Previous studies in unstressed animals fed without restriction
demonstrated a normal circadian rhythm of plasma corticoste-
rone in the rat, ranging from low values of approximately 2
g/dl at approximately 9 A.M. to peak values of about 21 g/dl
at 7 P.M. [9]. A recent report indicates that free corticosterone,
which is about 20% of total serum corticosterone, exhibits the
same diurnal variation [10].
Adrenalectomizedanimals with hormone replacement. Stud-
ies were performed to correlate the rate of delivery of aldoster-
one and the replacement of corticosterone with plasma levels of
aldosterone and corticosterone. Aldosterone was chronically
infused, via osmotic minipumps at variable rates for 5 days into
adrenalectomized animals not treated with corticosterone. Fig-
ure 2 demonstrates mean plasma values in five pairs of animals
in which each pair was infused at different delivery rates
ranging from 1.25 g/10O g body weight per day to 20 tg/l00 g
body weight per day and shows a nearly linear relationship over
the dose range used. At the lowest level of 1.25 g/l00 g body
weight per day, the plasma level was 8.5 ngldl, and at 0.8 g/l00
g body weight per day, not shown in the figure, the level was 4.1
0.2 ngldl in 18 animals. Since the plasma level in unstressed
control animals was approximately 5 ngldl, these results indi-
cate for the first time that the basal endogenous production rate
of aldosterone is approximately 1.0 g/100 g body weight per
day. Previous studies on the endogenous production rate of
aldosterone have been performed in the stressed rat and demon-
strated a rate of 3.0 to 3.5 g/100 g body weight [II, 12].
Meyer et al [2] reported that implantation of corticosterone
pellets resulted in stable plasma levels of the hormone for about
15 days, although transiently higher levels were recorded 2 to 3
days after surgery, Serial measurements of plasma corticoste-
rone in five animals for 7 days after implantation of two pellets
of 60 mg of corticosterone demonstrated a similar profile with
stable plasma levels between 3 and 7 days. The plasma level of
corticosterone 6 to 7 days after adrenalectomy and implantation
of two pellets of 60 mg of corticosterone was 9.8 0.5 .tg/dl in
12 animals: This value was not statistically different from basal
midmorning levels in control animals with intact adrenal glands.
Since previous workers have used dexamethasone for gluco-
corticoid replacement in adrenalectomized animals, usually
administered in a dose of approximately 5 ig/100 g body weight
per 12 hr in the rat by bolus subcutaneous injection [3, 13].
Experiments were performed with that regimen to determine
plasma levels of dexamethasone in three animals for approxi-
mately 3 hr after injection. Plasma levels of dexamethasone
Delivery rate, g/1OOg body wt/day
Fig. 2. Plasma levels of aldosterone during the delivery of the hormone
via Osmotic minipumps, at rates varying between 1, 25 and 20 p.g/100 g
body weight. Studies were performed 5 days after adrenalectomy and
insertion of the pump. Each closed circle is the average value of two
animals infused at the same rate.
rapidly increased after injection to an average level of 3.1 0.2
g/dl at 60 mm, after which plasma levels slowly rose to 3.8
0.3 g/dl 180 mm after injection.
Physiological replacement of aldosterone and corlicosterone
in adrenalectomized animals. The goal in these experiments
was to establish a hormone-replaced adrenalectomized animal
comparable to control animals in the basal unstressed state.
Two different criteria were used to determine the dose levels of
aldosterone and corticosterone.
The first method used basal plasma levels in unstressed
animals as a guide for replacement. Basal plasma levels of
aldosterone were achieved by a chronic infusion rate of 0.8
g/l00 g body weight per day, providing a stable plasma level of
4.1 0.2 ng/dl for up to 7 days, as noted above. The basal level
of corticosterone, of approximately 10 Lg/dl, was achieved by
the subcutaneous implantation of two pellets of 60 mg cortico-
sterone resulting in a mean plasma level of 9.8 0.5 tg/dl
between 5 and 7 days after surgery. Since previous studies
suggest that the biological effects of transient high plasma levels
of glucocorticoids may persist for at least 48 hr [14], all
physiologic experiments were performed at least 5 days after
replacement therapy was initiated because of the higher plasma
corticosterone levels within the first few days of pellet
implantation.
The second method used a physiological parameter because it
was assumed that basal hormonal replacement therapy should
result in electrical properties in target epithelia comparable to
those found in control animals with intact adrenal glands. Since
aldosterone responsive epithelia in the distal nephron is rela-
tively inaccessible to direct analysis, the potential difference
across the large intestine was used as an index of mineralocor-
ticoid action.
Figure 3 demonstrates that the profile of potential difference
along the colon of control animals and the mean value of 26.6
6.6 mV (lumen negative) at 2.5 cm from the anus agreed with
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corticosterone (lower panel) in basal() and stressed (EJ) conditions.
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CM from anus
Fig. 3. The rransmural potential difference along the course of the distal
colon for five control rats (0) with intact adrenal glands and five
nonreplaced adrenalectomized animals (•). Mean SCM of values at
different sites along the colon are shown.
previous reports [15]. Following adrenalectomy the potential
difference was reduced approximately 50% between 2 and 4 cm
of the distal colon.
The effect of aldosterone on colonic potential difference in
ten adrenalectomized animals infused with aldosterone at vary-
ing delivery rates is shown in Figure 4. To avoid the possible
action of corticosterone to stimulate potential difference, gluco-
corticoids were not administered to these animals. Inspection of
Figure 4 shows that a normal potential difference of 20 to 30 mV
was associated with plasma aldosterone levels of 5 to 10 ng/dl;
at plasma levels greater than 25 ngldl a marked increase in
potential difference was observed. These animals gained an
average 5.3 g/day in body weight.
Additional dose response studies were performed in five pairs
of animals, in which each pair was implanted with a different
amount of corticosterone, in addition to receiving the physio-
logic replacement dose of aldosterone of 0.8 g/100 g body
weight per day. Results, not shown, indicated that a plasma
level of corticosterone greater than 5 g/dl was associated with
an increase in colonic potential difference above control.
Table 1 lists the colonic potential difference in unstressed
control animals and adrenalectomized rats with basal levels of
aldosterone and various plasma levels of corticosterone or
dexamethasone. It is apparent that the colonic potential differ-
ence in substituted animals was comparable to control animals
only when the sustained level of corticosterone was less than 8
g/dl. In substituted animals with higher plasma levels of
corticosterone the colonic potential difference was increased to
70 to 80 mV. Inspection of Table 1 also demonstrates that
administration of dexamethasone in a dose of 5 g/l00 g body
weight/12 hr was associated with a marked increase in colonic
potential difference. In addition to the changes in the electrical
properties of large intestine, loss in body weight was induced by
the administration of dexamethasone and sustained plasma
levels of corticosterone greater than or equal to 8 g/dl,
compared to unstressed control and adrenalectomized animals
with lower plasma levels of corticosterone. These data suggest
therefore, that sustained plasma levels of corticosterone of less
than 8 g/dl provide physiological replacement, while higher
levels alter basal epithelial function and increase tissue
catabolism.
Discussion
This study demonstrates a method for adrenal hormone
replacement in the rat in which stable plasma levels of aldoster-
one and corticosterone can be maintained for at least 7 days.
Moreover, results of this study indicate that basal physiological
replacement of aldosterone in adrenalectomized animals re-
quires an infusion rate of approximately 1 g/l00 g body weight
per day and plasma levels of 4 to 5 ng/dl; this plasma level
compares favorably with the value in unstressed animals with
intact adrenal glands. Determination of the physiological level
of corticosterone replacement was complicated by an inability
to simulate the normal diurnal variation in plasma levels found
in the rat and other mammals. Nevertheless, in regard to the
electrical properties of an epithelium responsive to aldosterone,
physiological replacement was achieved with sustained plasma
levels less than 8 g/dl, since higher sustained plasma levels
were associated with an increase in the potential difference of
large intestine and signs of increased catabolism reflected by
loss in body weight. These results agree with clinical findings in
Cushing disease where sustained levels of cortisol within the
physiological diurnal range are known to cause signs of hyper-
corticism. It should be noted that the basal potential difference
in colon and other epithelia responsive to aldosterone may
represent several secretory and absorptive pathways directly or
indirectly influenced by aldosterone and/or corticosterone. An
elucidation of the role of adrenal hormones on basal and
augmented potential difference will require further studies in
which in vivo action can be correlated with occupancy of
specific cellular receptor sites.
An analysis of the in vivo action of adrenal hormones has an
important role in efforts to elucidate their mechanism of action
and their quantitative effects on the ionic transport rates, since
epithelial tissue samples may be altered during preparation for
in vitro studies. In addition, chronic administration of adrenal
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390 Martin et a!
Table 1. Transmural potential difference in distal colon of control and adrenalectomized animals with replacement hormone therapya
Group
Body weight
giday
Potential difference, mV
lumen negative
Aldosterone
ngld!
Corticosterone
p.gldl
Dexamethasone
jsg/dl
Control (5) +5.3 0.6 26.6 6.6 4.6 0.07 9.0 1.8 —
Intact adrenals
Adrenalectomy (4) +3.4 0.8 11.2 2.0' Undetectable Undetectable —
No replacement
Adrenalectomy (7) +5.7 1.2 32.4 6.8 3.8 0.3 3.0 0.2b
Corticosterone, 2 pellets 20 mg
Aldosterone, 0.8 gI100 g body wt/24 hr
Adrenalectomy (6) —4.4 0.8 80.3 5.6b 3.9 0.3 8.0 1.3 —
Corticosterone, 2 pellets 60 mg
Aldosterone, 0.8 g/100 g body wt124 hr
Adrenalectomy (6) —5.3 1.1 69.0 8.Ob Undetectable 10.2 0.9 —
Corticosterone, 2 pellets 60 mg
Adrenalectomy (5) —5.6 0.6 67.2 5.Ob 3.8 0.2 — 3.8 0.3
Dexamethasone, 5 jzg/100 g body wt/12 hr
Aldosterone, 0.8 p.g/100 g body wt124 hr
The number in parenthesis indicates the number of animals studied. The transmural potential difference was measured 2.5 cm from the anus.
b The value is statistically different from control at P < 0.05.
hormones is necessary for in vitro experiments designed to
examine the action of chronic physiologic elevations of plasma
aldosterone or glucocorticoid hormones. The interpretation of
previous experiments in which those agents have been adminis-
tered to animals has been unclear for several reasons. First, the
effect of hormonal substances administered to experimental
animals with intact adrenal glands may be obscured by in-
creased endogenous production of aldosterone and either corti-
costerone or cortisone due to stress [11, 16]. Second, the action
of adrenal hormones may be modified in adrenalectomized
animals treated only with saline solutions because of changes in
intracellular ion concentration [17]. Third, organ perfusion is
markedly reduced in adrenalectomized animals not replaced
with glucocorticoid hormones [18], and conversely, renal blood
flow and GFR increase above control by the administration of
pharmacological doses of glucocorticoid agents [19, 20].
The results of this study also demonstrate that the administra-
tion of synthetic glucocorticoids by intermittent injection, in a
manner designed to provide an amount equivalent to the
estimated daily production of the endogenous hormone, may
result in high plasma levels of the synthetic agent. The subcuta-
neous injection of 5 g/100 g body weight of dexamethasone
was associated with a plasma level of approximately 4 jg/dl for
at least 3 hr. This value was similar to the estimated physiologi-
cal replacement level of corticosterone. Since dexamethasone
is largely available to receptor sites because of its low affinity
binding to albumin [21], in contrast to corticosterone of which
about 80% of the amount in plasma is tightly bound to transcor-
tin [22, 23], the observed plasma levels were in a pharmacologi-
cal range and caused hyperpolarization of the transmural poten-
tial different in colon and loss in body weight.
Synthetic glucocorticoids could be administered in this ani-
mal model with the osmotic minipump for glucocorticoid re-
placement. Although not primarily related to the results of this
study, it should be noted that the physiological replacement
dose of synthetic hormones cannot be calculated with confi-
dence from published reports on relative potencies, since those
data are mainly derived from comparisons on anti-inflamma-
tory, lymphopenic, and glycolytic effects [24]. Studies related
to relative mineralocorticoid action of glucocorticoid hormones
involved measurements of electrolyte excretion after in vivo
administration, and changes in GFR and relative binding to
plasma proteins were not considered [19]. In the present study
we elected to use the endogenous glucocorticoid in the rat since
most biological studies are usually concerned with the action of
adrenal derivatives within the physiological range.
In summary, an experimental animal model is described
which permits an evaluation of the chronic action of aldoster-
one and corticosterone on epithelial function under conditions
where the plasma levels of each type of major adrenal hormone
can be regulated by experimental design. Experiments with this
model have demonstrated the basal physiological replacement
level of plasma aldosterone and the plasma level of corticoste-
rone which does not influence the electrical properties of an
aldosterone responsive epithelium.
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